{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:13:59Z","timestamp":1790900039528,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EB 187\/8-1"],"award-info":[{"award-number":["EB 187\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.esmoop.2023.101201","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T19:52:59Z","timestamp":1679601179000},"page":"101201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy\u2014results of a prospective, multicenter German observational study"],"prefix":"10.1016","volume":"8","author":[{"given":"M.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Hutzschenreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kollendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Z\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Frank-Gleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lorentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zingerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Stosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Burkholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.-D.","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2023.101201_bib1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000510258","article-title":"Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper","volume":"43","author":"W\u00f6rmann","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101201_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FTD.0000000000000238","article-title":"Individual 5-fluorouracil dose adjustment via pharmacokinetic monitoring versus conventional body-area-surface method: a meta-analysis","volume":"38","author":"Yang","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101201_bib5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101201_bib7","first-page":"381","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice","volume":"15","author":"Wilhelm","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2023.101201_bib8","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/jco.2014.32.15_suppl.3574","article-title":"Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: U.S.-based clinical practices experience","volume":"32","author":"Braiteh","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101201_bib9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1515\/cclm-2018-1177","article-title":"Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects","volume":"57","author":"Mindt","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib10","first-page":"203","article-title":"Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens","volume":"10","author":"Saam","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.101201_bib11","unstructured":"European Medicines Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020 Available at https:\/\/www.fagg.be\/sites\/default\/files\/content\/dhpc_fluorouracil_nl_-_website.pdf. Accessed March 17, 2023."},{"issue":"1","key":"10.1016\/j.esmoop.2023.101201_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv Enzyme Regul"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101201_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A\u00a0pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101201_bib14","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group","volume":"26","author":"Schwab","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101201_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.dld.2020.11.004","article-title":"When helping the minority of patients may hurt the majority: the case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring","volume":"53","author":"Tron","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101201_bib16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.1978.278","article-title":"Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion","volume":"38","author":"Hillcoat","year":"1978","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101201_bib17","first-page":"374","article-title":"Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug","volume":"7","author":"Seitz","year":"1983","journal-title":"Gastroenterol Clin Biol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101201_bib19","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-07-1529","article-title":"5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer","volume":"14","author":"Di Paolo","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101201_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13110416","article-title":"Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure","volume":"13","author":"Dolat","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101201_bib21","first-page":"119","article-title":"Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens","volume":"13","author":"Kline","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101201_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00280-016-3184-6","article-title":"Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial","volume":"78","author":"Denda","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101201_bib23","first-page":"219","article-title":"Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer","volume":"13","author":"Goldstein","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"91","key":"10.1016\/j.esmoop.2023.101201_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19910","article-title":"Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion","volume":"19","author":"Freeman","year":"2015","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101201_bib25","doi-asserted-by":"crossref","first-page":"A139","DOI":"10.1016\/j.jval.2013.03.680","article-title":"Cost-effectiveness of pharmacokinetic dosing of 5-fluorouracil in metastatic colorectal cancer in the United Kingdom","volume":"16","author":"Becker","year":"2013","journal-title":"Value Heal"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:19Z","timestamp":1761856159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923004246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2059702923004246"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101201","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy\u2014results of a prospective, multicenter German observational study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101201"}}